Does Testosterone Cause Prostate Cancer?

Few topics in men’s health generate more fear, confusion, and misinformation than testosterone therapy. For decades, men have been told some version of the same warning. If you take testosterone, you will increase your risk of prostate cancer. For many physicians, this belief became so deeply ingrained that it was rarely questioned. It was treated as established fact, repeated as medical doctrine, and used to discourage countless men from addressing low testosterone and the very real health consequences that come with it.

The problem is that this belief has been built far more on fear and outdated assumptions than on modern evidence.

This is one of the most persistent myths in men’s health, and it has done enormous damage. It has caused men to avoid treatment that could improve strength, energy, cognition, metabolic health, sexual function, and overall quality of life. It has also shaped clinical decisions in ways that often fail to reflect what decades of more recent research actually show.

The real question is not whether testosterone deserves fear. The real question is whether the fear surrounding testosterone is supported by evidence. Once you examine the data carefully, the answer becomes much more complicated than most men have been led to believe.

Where the Fear Came From

Much of the fear surrounding testosterone and prostate cancer can be traced back to one idea that became deeply embedded in medical teaching: testosterone fuels prostate cancer. That belief did not appear out of nowhere. It came from early research by Charles Huggins and Clarence Hodges in the 1940s showing that lowering testosterone through castration or estrogen therapy could reduce markers of disease activity in men with metastatic prostate cancer. Their work was important, and it helped establish hormone suppression as a treatment strategy for advanced disease. The problem is not that the original observation was meaningless. The problem is that it was applied far beyond the setting in which it was studied.

The original work involved men with advanced metastatic prostate cancer, not healthy men with low testosterone, not aging men considering testosterone replacement, and not men trying to preserve strength, sexual function, metabolic health, and vitality. That distinction matters. A treatment observation in men with late-stage disease was gradually transformed into a sweeping belief that testosterone itself causes prostate cancer or universally accelerates it. That leap shaped decades of clinical practice, but it was a leap the evidence did not justify.

This is where conventional thinking became overly simplistic. Complex biology was reduced to a single sentence: testosterone feeds prostate cancer. Once that sentence became medical dogma, it became easy to repeat and hard to question. Men were warned away from testosterone therapy, physicians became fearful of prescribing it, and the broader health consequences of low testosterone were often minimized or ignored.

Modern research has challenged that old assumption. Morgentaler and Traish, in their work on the saturation model published in European Urology, argued that prostate tissue appears to respond to testosterone only up to a certain threshold, after which additional testosterone does not continue to stimulate prostate growth in a linear fashion. That model helps explain why restoring testosterone from deficient levels into a normal physiologic range does not appear to behave the same way as giving testosterone to men with advanced hormone-sensitive metastatic disease.

That difference is crucial. The question is not whether hormones matter in prostate cancer. They clearly do. The question is whether normal testosterone replacement in a deficient man carries the same meaning as androgen stimulation in metastatic disease. Those are not the same clinical situations, and treating them as though they are the same is one of the reasons this myth has survived for so long.

Even mainstream endocrine guidelines now take a more nuanced position than the old fear-based narrative. The Endocrine Society’s clinical practice guideline recommends diagnosing hypogonadism only in men with consistent symptoms and repeatedly low testosterone levels, and it supports testosterone therapy in appropriately selected hypogonadal men while also recommending prostate monitoring and shared decision-making. That is very different from the simplistic idea that testosterone therapy automatically causes prostate cancer.

This is why the origin of the fear matters. If a belief was built on data from men with advanced metastatic disease, then applied broadly to men without that disease, we need to ask whether the conclusion still holds. In this case, decades of later research have made the answer far less certain than conventional medicine once suggested. Testosterone deserves respect, monitoring, and clinical judgment. It does not deserve blind fear.

What the Evidence Actually Shows

When you move beyond decades of dogma and look carefully at the modern evidence, the story surrounding testosterone and prostate cancer looks very different than most men expect. The fear-based narrative suggests a simple relationship: higher testosterone increases prostate cancer risk, and lower testosterone protects against it. If that were true, the evidence should be straightforward. Men with higher testosterone levels should consistently develop more prostate cancer, more aggressive prostate cancer, and worse outcomes. But that is not what the research shows.

Large observational studies, systematic reviews, and meta-analyses have repeatedly failed to demonstrate convincing evidence that testosterone therapy increases prostate cancer risk in men without active disease. Research published in European Urology and multiple major urology journals has consistently challenged the long-standing belief that testosterone replacement therapy meaningfully increases prostate cancer incidence. In fact, despite millions of men receiving testosterone therapy over the past several decades, the feared explosion in prostate cancer rates simply has not materialized.

What makes the data even more interesting is that some studies suggest the opposite of what conventional thinking would predict. Low testosterone has been associated in multiple studies with more aggressive prostate cancer, higher-grade disease, and worse outcomes after diagnosis. Research published in journals such as BJU International and The Journal of Urology has shown associations between low testosterone levels and higher Gleason scores, more advanced disease at presentation, and poorer prognostic features.

If testosterone were simply fueling prostate cancer in a direct linear way, this pattern would make little sense. We would expect men with the highest testosterone levels to consistently fare the worst. Instead, what the evidence increasingly suggests is that the relationship between testosterone and prostate cancer is far more complex and far more nuanced than decades of conventional teaching implied.

This makes biological sense when you step back and look at testosterone through a broader lens. Testosterone is not a toxin, and it is not some dangerous substance the body was never meant to have. It is one of the foundational hormones in male physiology. Testosterone plays a central role in maintaining muscle mass, bone density, metabolic function, insulin sensitivity, cardiovascular health, cognitive function, motivation, resilience, immune function, and sexual health. In many ways, testosterone helps determine how well a man ages and how resilient he remains over time.

This is where I believe the conversation around testosterone often becomes dangerously oversimplified. Too much attention is placed on a theoretical risk that modern evidence has repeatedly failed to confirm, while far too little attention is placed on the very real and measurable consequences of testosterone deficiency. Low testosterone is not benign. It is associated with loss of muscle mass, increased fat accumulation, worsening insulin resistance, reduced bone density, cognitive decline, depression, frailty, and declining quality of life.

The question should not simply be whether testosterone might theoretically influence prostate tissue. Of course hormones matter. The more important question is how testosterone affects the overall health, resilience, and long-term function of the man sitting in front of you. Once you start asking that question, the discussion becomes much more sophisticated than the simplistic fear-based narrative that has dominated medicine for decades.

The evidence does not support blind fear. It supports nuance. It supports careful monitoring. It supports individualized decision-making. Most importantly, it supports moving beyond outdated assumptions and asking better questions about what truly improves both longevity and quality of life.

The Saturation Model

One of the most important concepts in understanding testosterone and prostate health is something known as the saturation model. This model has significantly changed how many experts think about the relationship between testosterone and prostate tissue because it challenges one of the most deeply ingrained assumptions in men’s health.

The traditional belief was simple and highly intuitive. More testosterone meant more stimulation of prostate tissue, more prostate growth, and greater cancer risk. According to that model, testosterone behaved almost like fuel poured onto a fire. The higher the testosterone level, the more aggressively the prostate or prostate cancer would respond. That framework shaped decades of medical thinking, but the problem is that the biology does not appear to behave that way.

The saturation model proposes something very different. Prostate tissue appears to respond to testosterone only up to a certain threshold. Once androgen receptors within prostate tissue become saturated, increasing testosterone levels beyond that point does not continue to stimulate additional prostate growth or cancer activity in a meaningful linear fashion. In other words, the response is not endless. There appears to be a ceiling.

This model helps explain one of the biggest contradictions in the old testosterone narrative. If testosterone truly drove prostate cancer in a simple dose-dependent way, then men with the highest testosterone levels should consistently have the highest prostate cancer rates and the worst outcomes. That is not what the evidence shows. Study after study has failed to demonstrate a clear linear relationship between higher physiologic testosterone levels and increased prostate cancer risk.

Research from Abraham Morgentaler and colleagues has been central to advancing this understanding. Their work challenged decades of outdated dogma by demonstrating that prostate tissue may be highly sensitive to changes in testosterone at very low levels, but much less responsive once physiologic androgen levels are reached.

This distinction is critical because it helps explain why restoring testosterone from deficient levels into a normal physiologic range often improves health without endlessly stimulating the prostate. It also explains why men with severely low testosterone may notice PSA rises modestly after beginning testosterone therapy. In many cases, this does not indicate dangerous cancer growth. It may simply reflect prostate tissue responding to a return toward normal hormonal physiology.

The fear-based narrative surrounding testosterone assumes any increase in testosterone is inherently dangerous to the prostate. The saturation model suggests that assumption is far too simplistic. Hormonal biology is more nuanced than that. There is a profound difference between restoring testosterone to healthy physiologic levels in a deficient man and exposing advanced metastatic prostate cancer to hormonal stimulation. Those are completely different clinical scenarios, yet for decades they were often treated as though they were the same.

This is where the old model begins to break down. The evidence increasingly suggests that testosterone deficiency and testosterone optimization deserve far more thoughtful discussion than men are typically offered. The goal should not be reflexively suppressing testosterone or fearing it. The goal should be understanding how testosterone functions within the broader context of male health, prostate biology, and long-term resilience.

Once you understand the saturation model, it becomes much harder to accept the simplistic claim that testosterone automatically fuels prostate cancer in a predictable linear way. The evidence simply does not support that conclusion, and men deserve a much more honest conversation about what modern research actually shows.

Why Low Testosterone Carries Real Risk

This is the part of the testosterone conversation many men never hear, and it may be one of the biggest failures in modern men’s health. For decades, enormous attention has been placed on the theoretical risks of testosterone therapy, particularly the fear of prostate cancer. At the same time, the risks of untreated low testosterone have often been minimized, ignored, or dismissed as an inevitable part of aging. That is a major problem because low testosterone is not benign, and treating it as harmless has left many men silently declining for years without understanding what is happening to their bodies.

Testosterone is one of the foundational hormones in male physiology. When testosterone declines, the consequences extend far beyond sexual function. The effects are systemic and often progressive. Muscle mass declines. Strength fades. Bone density weakens. Body fat increases, particularly visceral fat. Insulin resistance worsens. Energy drops. Motivation declines. Mood changes become more common. Cognitive function often suffers. Sexual health deteriorates. These changes do not happen in isolation. They affect how men age, how resilient they remain, and how well they function physically, mentally, and metabolically over time.

The research on testosterone deficiency is substantial and increasingly difficult to ignore. Studies have shown strong associations between low testosterone and increased risk of metabolic syndrome, type 2 diabetes, cardiovascular disease, frailty, and all-cause mortality. Other studies have linked testosterone deficiency to depression, reduced cognitive performance, loss of muscle mass, and declining quality of life.

Every path carries risk. Aging with untreated testosterone deficiency carries predictable biological consequences. Those consequences are not theoretical. They are measurable, visible, and often progressive. Testosterone therapy, by contrast, carries risks that deserve thoughtful monitoring and clinical judgment, but many of those risks have been exaggerated or oversimplified, particularly in the context of prostate cancer.

This is where I believe men need to think much more critically. The real question is not simply whether testosterone therapy carries any risk. Of course every medical decision carries risk. The more important question is whether the risk of treatment outweighs the risk of doing nothing. That is a very different conversation, and it is the conversation many men never get to have.

Too often, men are told to avoid testosterone out of fear while no one fully explains what untreated testosterone deficiency may cost them over the next decade. They are warned about theoretical future risks while already experiencing measurable present decline. That imbalance makes no sense.

The real risk for many men may not be testosterone therapy. The real risk may be allowing preventable decline to continue unchecked out of fear, outdated dogma, or incomplete understanding of the evidence. Men deserve better than that. They deserve clear, evidence-based conversations that account for both sides of the equation and focus on what truly matters: preserving strength, vitality, resilience, independence, and quality of life as they age.

PSA, Testosterone, and Rational Monitoring

This is another area where fear often overrides good clinical judgment. Many men are told that an elevated PSA automatically disqualifies them from testosterone therapy, as if one lab value settles the entire question. I believe that is far too simplistic. PSA is useful, but it is also imperfect. It should never be interpreted in isolation, and it should never be allowed to replace a thoughtful clinical assessment.

PSA is a marker, not a diagnosis. It does not automatically mean cancer is present, and it does not automatically identify dangerous cancer. PSA can rise for many reasons, including prostate enlargement, inflammation, infection, recent ejaculation, cycling, urinary retention, or simple biological variation. Research has shown that PSA levels can fluctuate meaningfully between tests, which is why reacting emotionally to one elevated number often leads men down the wrong path.

This becomes even more important when testosterone therapy is being considered. Restoring testosterone from deficient levels to normal physiologic levels can sometimes cause a modest PSA increase, not necessarily because cancer is growing, but because prostate tissue is responding to a healthier hormonal environment. That is a very different situation from uncontrolled PSA acceleration, concerning MRI findings, or evidence of aggressive disease.

The Endocrine Society clinical practice guideline recommends careful diagnosis, appropriate patient selection, and prostate monitoring when testosterone therapy is used. That is reasonable. Monitoring is not the problem. The problem is confusing monitoring with panic. A rational approach follows PSA trends over time, looks at the rate of change, considers prostate size, evaluates symptoms, and uses imaging when appropriate. It does not treat every PSA movement as a crisis.

The TRAVERSE prostate safety analysis also adds an important perspective. In men with hypogonadism who were carefully screened and monitored, testosterone therapy did not show higher rates of high-grade prostate cancer compared with placebo. That does not mean testosterone therapy requires no caution. It means the old fear-based assumption that testosterone automatically creates dangerous prostate outcomes is not supported by the best modern evidence.

The right question is not simply whether PSA is elevated. The right question is what the PSA is doing over time and what the entire clinical picture suggests. Is the PSA stable or rising rapidly? Has it been repeated under better testing conditions? What does the MRI show? Is the prostate enlarged? Are there signs of inflammation? Is the man symptomatic? These are the questions that matter because context changes everything.

The goal should never be to react emotionally to a single lab value. The goal should be a thoughtful interpretation of the broader clinical picture. Testosterone therapy deserves respect, monitoring, and sound judgment. It does not deserve blind fear.

Final Thoughts

I believe the conversation around testosterone and prostate cancer has been dominated by fear for far too long, and much of that fear is rooted in outdated assumptions that no longer align with what modern evidence actually shows. For decades, men have been warned about testosterone as though it were inherently dangerous, despite growing evidence that the relationship between testosterone and prostate cancer is far more nuanced than conventional medicine once believed. That should concern every man, because fear-driven medicine rarely leads to the best long-term decisions.

I believe men deserve better than reflexive warnings, outdated dogma, and oversimplified thinking. They deserve thoughtful, evidence-based conversations that look at the full picture, not just theoretical risk. The real question is not whether testosterone should automatically be feared. The real question is how to make intelligent decisions that protect both longevity and quality of life while preserving the biological systems that matter most as men age.

This is where I think the conversation becomes much more honest. Strength matters. Vitality matters. Cognition matters. Independence matters. Quality of life matters. These are not secondary concerns. They are central to how well a man lives. Too often, medicine becomes so focused on avoiding theoretical future risk that it ignores the very real and measurable consequences of testosterone deficiency happening right now.

The goal should not be to fear testosterone. The goal should be to understand it, monitor it intelligently, and apply sound clinical judgment when making treatment decisions. For many men, the greatest risk may not be testosterone therapy itself. The greater risk may be allowing preventable decline to continue unchecked because of fear, misinformation, or outdated beliefs.

If you have avoided testosterone therapy out of fear, or if you have been told testosterone is dangerous without a meaningful discussion of the evidence, I encourage you to ask harder questions and take a closer look at the data. Watch my full discussion on testosterone and prostate cancer, read Fight Cancer Like a Man, or schedule a consultation if you want personalized guidance on testosterone optimization and men’s health.

Watch my podcasts on testosterone and prostate cancer:

Prostate Cancer and Testosterone: What Men Are Never Told

The strongest decisions are rarely made from fear. They are made from clarity, evidence, and a clear understanding of what is truly at stake.

About Dr. Stephen Petteruti

Dr. Stephen Petteruti is a physician focused on men’s health, hormone optimization, longevity, and prostate cancer care. His approach challenges conventional thinking by focusing on root causes, metabolic health, and long-term vitality. His goal is not simply helping patients live longer, but helping them preserve strength, energy, resilience, and quality of life as they age.

Learn more at https://www.drstephenpetteruti.com/ 

References

1. Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;1:293-297.
2. Morgentaler A, Traish AM. Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur Urol. 2009;55(2):310-320.
3. Morgentaler A. Testosterone therapy in men with prostate cancer: scientific and ethical considerations. J Urol. 2013;189(1 suppl):S26-S33.
4. Morgentaler A, Bruning CO 3rd, DeWolf WC. Occult prostate cancer in men with low serum testosterone levels. JAMA. 1996;276(23):1904-1906.
5. Boyle P, Koechlin A, Bota M, et al. Endogenous and exogenous testosterone and prostate cancer: decreased-, increased-, or null-risk? Eur Urol. 2016;70(4):642-651.
6. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744.
7. Cui Y, Zong H, Yan H, Zhang Y. The effect of testosterone replacement therapy on prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2014;17(2):132-143.
8. Kaplan AL, Hu JC, Morgentaler A, Mulhall JP, Schulman CC, Montorsi F. Testosterone therapy in men with prostate cancer. Eur Urol. 2016;69(5):894-903.
9. Khera M, Bhattacharya RK, Blick G, et al. Improved sexual function with testosterone replacement therapy in hypogonadal men. J Urol. 2013;190(5):1828-1833.
10. Isom-Batz G, Bianco FJ Jr, Kattan MW, et al. Testosterone as a predictor of pathological stage in clinically localized prostate cancer. J Urol. 2005;173(6):1935-1937.
11. Massengill JC, Sun L, Moul JW, et al. Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J Urol. 2003;169(5):1670-1675.
12. Dai B, Qu YY, Kong YY, et al. Low pretreatment serum total testosterone is associated with a high incidence of Gleason score upgrading in prostate cancer patients after radical prostatectomy. Asian J Androl. 2012;14(4):543-546.
13. Xylinas E, Ploussard G, Durand X, et al. Low pretreatment total testosterone is associated with high-grade prostate cancer. BJU Int. 2011;107(9):1403-1408.
14. Corona G, Monami M, Rastrelli G, et al. Testosterone and metabolic syndrome: a meta-analysis study. J Sex Med. 2011;8(1):272-283.
15. Kelly DM, Jones TH. Testosterone and cardiovascular risk in men. Front Horm Res. 2014;43:1-20.
16. Yeap BB. Testosterone and ill-health in aging men. Nat Clin Pract Endocrinol Metab. 2009;5(2):113-121.
17. Traish AM, Miner MM, Morgentaler A, Zitzmann M. Testosterone deficiency. Am J Med. 2011;124(7):578-587.
18. Malkin CJ, Pugh PJ, Jones RD, Kapoor D, Channer KS, Jones TH. Testosterone for secondary prevention in men with coronary artery disease. Heart. 2006;92(8):1056-1061.
19. Shores MM, Moceri VM, Sloan KL, Matsumoto AM, Kivlahan DR. Low serum testosterone predicts incident depression in older men. Arch Gen Psychiatry. 2005;62(7):750-755.
20. Wu FCW, Tajar A, Pye SR, et al. Hypothalamic-pituitary-testicular axis disruptions in older men are linked to sexual symptoms and frailty. N Engl J Med. 2010;363(2):123-135.
21. Eastham JA, Riedel E, Scardino PT, et al. Variation of serum prostate-specific antigen levels: an evaluation of year-to-year fluctuations. JAMA. 2003;289(20):2695-2700.
22. Nixon RG, Wener MH, Smith KM, Parson RE, Strobel SA, Brawer MK. Biological variation of prostate-specific antigen levels in healthy men. Urology. 1997;50(4):496-499.
23. Bhatt DL, Mehta C, Steg PG, et al. Cardiovascular safety of testosterone-replacement therapy. N Engl J Med. 2023;389(2):107-117.
24. Lincoff AM, Bhasin S, Flevaris P, et al. Prostate safety events during testosterone replacement therapy in men with hypogonadism: results from the TRAVERSE trial. J Urol. 2024;211(2):343-351.